Table 1.
Changes from baseline and time saved for 2 mg AD04 compared with other arms combined
| Endpoint | Mean change (SE) to month 18 | Mean difference (95% CI) | Time saved (months – 95% CI) | |
|---|---|---|---|---|
| 2 mg AD04 arm | Other study arms combined | |||
| aADAS | 3.0 (1.7) | 6.7 (0.8) | −3.6 (−7.3, 0.0) p=0.0510 | 8.7 (−1.8, 19.3) p=0.1045 |
| aADL | −8.3 (2.7) | −14.2 (1.4) | 5.9 (−0.1, 11.9) p=0.0558 | 9.5 (1.2, 17.9) p=0.0251 |
| CDR-sb | 1.3 (0.4) | 1.9 (0.2) | −0.6 (−1.4, 0.2) p=0.1491 | 6.6 (−1.8, 15.1) p=0.1248 |
| Composite | 2.4 (1.8) | 6.3 (0.9) | −3.8 (−7.8, 0.1) p=0.0574 | 11.1 (2.2, 20.0) p=0.0143 |
| ADAS-Cog | 3.5 (1.4) | 6.0 (0.7) | −2.5 (−5.5, 0.5) p=0.1036 | 6.2 (−4.4, 16.7) p=0.2503 |
| ADCS-ADL | −5.9 (1.7) | −8.6 (0.8) | 2.7 (−1.1, 6.4) p=0.1626 | 6.8 (−1.6, 15.3) p=0.1135 |
| gTCT1: aADAS, aADL, and CDR-sb | 8.3 (1.2, 15.5) p=0.0224 | |||
| gTCT2: CDR-sb and Composite | 8.7 (1.3, 16.1) p=0.0208 | |||
| gTCT3: ADAS-Cog, ADCS-ADL, and CDR-sb | 6.6 (−0.7, 14.0) p=0.0761 | |||